Why StoneCo and bluebird bio are wonderful buys right now.
News & Analysis: Bluebird Bio
Both of these biotech companies recently released encouraging data from clinical trials.
Patients in its clinical trial continue to be nearly free of the disease's most serious symptoms.
Which of these two biotech companies is the better stock pick today?
Between a string of avoidable problems and instability in the market, bluebird bio might be in for a rough decade.
The startup aims to take on bluebird bio and Bristol Myers Squibb with its CAR-T therapy targeting BCMA for multiple myeloma.
Exelixis has vastly outperformed bluebird bio on the market of late, but will this trend continue?
The pharma giant and the smaller biotech will keep working together on a couple of promising CAR-T cancer therapies.
Who wins in a matchup between these two gene-editing leaders?
A major move by the Fed lifted the entire stock market, including this biotech stock.